Swedish pharmaceutical company OncoZenge AB (Nasdaq First North Growth Market:ONCOZ) announced on Monday that it has appointed Swedish Contract Development and Manufacturing Organisation (CDMO) Meribel Pharma Solutions, formerly Recipharm, as its CDMO for the Phase 3 clinical trial of BupiZenge, a local anaesthetic lozenge aimed at targeting oral pain.

The decision follows a refinement of the project scope in collaboration with Italian pharmaceutical company Molteni Farmaceutici, OncoZenge's pan-European licensing partner. The Phase 3 study is intended to support European regulatory approval of BupiZenge.

Meribel will handle development and production of clinical trial materials, supporting OncoZenge's Clinical Trial Application. OncoZenge cited Meribel's technical expertise, prior experience with BupiZenge formulations, and local presence in Sweden as key factors in the selection.